Lotte Biologics announced on June 4 that it will participate in the 2026 Bio International Convention (BioUSA) in San Diego, California.
BioUSA, organized by the Biotechnology Innovation Organization, is the largest global exhibition for the pharmaceutical and biotechnology industries, bringing together major pharmaceutical companies, investors, and research institutions to explore collaboration opportunities. Lotte Biologics has participated for five consecutive years since 2022.
The company plans to facilitate discussions with global clients through a visitor exchange area and private meeting rooms. It will also conduct an "in-booth presentation" to showcase its vision and business capabilities, along with programs related to antibody-drug conjugates (ADCs).
The in-booth presentations will take place three times during the event. On the first day, Lotte Biologics will introduce its development and production collaboration strategy with Asimov. The second day will feature a presentation on scale-up strategies based on computational fluid dynamics (CFD). The third day will focus on strategies for the digitalization of manufacturing processes to improve operational efficiency.
This year’s exhibition booth will also display photos and videos of the first plant at the Songdo Bio Campus, which is set to be completed in August. The presentation will highlight the plant's production processes and facilities, emphasizing its commercial production capabilities. Previously, the company received the 2026 CDMO Leadership Awards, underscoring the quality and execution capabilities of its contract development and manufacturing organization (CDMO) services.
A representative from Lotte Biologics stated, "We plan to enhance our global CDMO competitiveness based on the dual-site operations connecting Syracuse and Songdo."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.